Where Nordic biotech hits the wall — and why Hong Kong is the missing scale

The Nordic region produces life science innovation far out of proportion to its size. The lineage is real and well known: AstraZeneca and Novo Nordisk, the research density around Karolinska and the region's university hospitals, and beneath the famous names a deep, quietly world-class layer of medtech and biotech companies. On a per-capita basis, few places on earth invent more in human health.

And yet a familiar pattern repeats. A Nordic company does the hard part — strong science, a credible clinical or commercial signal, a defensible position — and then meets a wall. The wall has two sides. The first is capital: growth-stage funding in Europe is structurally thinner than in the United States, so exactly when a company needs to scale, the cheque sizes available at home shrink relative to the ambition. The second is market: the Nordic home market is sophisticated but small and fragmented, which means real scale has to be found abroad.

Most companies answer this by looking west, to the US. Fewer look east — and that is the gap we think is mispriced. Hong Kong offers the three things the wall is made of: depth of capital, the world's fastest-growing demand for validated health innovation driven by an ageing population, and the manufacturing and commercial scale to turn a good European product into a large one.

The catch is that Hong Kong is hard to enter alone. The barriers are not mainly scientific; they are regulatory, relational, and structural. A founder in Stockholm or Copenhagen rarely has the network, the local execution capacity, or the structuring know-how to do it well, and doing it badly is worse than not doing it at all.

That is the space we occupy. Not as a finder of cheques, but as a deliberate, structured bridge: we take companies that are already validated and give them the capital and the credible path into Hong Kong that they cannot build on their own — and we share in the value that connection creates. The innovation is Nordic. The missing scale is Hong Kong. Our work is making the link between them disciplined rather than accidental.